Overview

Phielix et al.: Hepatic Fat Content and Adipokines

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.
Phase:
N/A
Details
Lead Sponsor:
German Diabetes Center
Treatments:
Pioglitazone